annotation_id large_string | subject large_string | rsid large_string | gene large_string | genotype large_string | evidence_level large_string | phenotype_category large_string | drugs large_string | phenotypes large_string | annotation_text large_string | url large_string |
|---|---|---|---|---|---|---|---|---|---|---|
1156497684 | rs72547516 | rs72547516 | CYP1A2 | AA | 3 | Metabolism/PK | clozapine | null | Patients with the rs72547516 AA genotype and may have increased metabolism of clozapine as compared to patients with the AG, AT, TT or GG genotype. Other genetic and clinical factors may also influence clozapine metabolism. This annotation only covers the pharmacokinetic relationship between rs72547516 and clozapine an... | https://www.clinpgx.org/clinicalAnnotation/1156497684 |
1156497684 | rs72547516 | rs72547516 | CYP1A2 | AG | 3 | Metabolism/PK | clozapine | null | Patients with the rs72547516 AG genotype and may have decreased metabolism of clozapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clozapine metabolism. This annotation only covers the pharmacokinetic relationship between rs72547516 and clozapine and does not inc... | https://www.clinpgx.org/clinicalAnnotation/1156497684 |
1156497684 | rs72547516 | rs72547516 | CYP1A2 | AT | 3 | Metabolism/PK | clozapine | null | Patients with the rs72547516 AT genotype and may have decreased metabolism of clozapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clozapine metabolism. This annotation only covers the pharmacokinetic relationship between rs72547516 and clozapine and does not inc... | https://www.clinpgx.org/clinicalAnnotation/1156497684 |
1156497684 | rs72547516 | rs72547516 | CYP1A2 | GG | 3 | Metabolism/PK | clozapine | null | Patients with the rs72547516 GG genotype and may have decreased metabolism of clozapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clozapine metabolism. This annotation only covers the pharmacokinetic relationship between rs72547516 and clozapine and does not inc... | https://www.clinpgx.org/clinicalAnnotation/1156497684 |
1156497684 | rs72547516 | rs72547516 | CYP1A2 | TT | 3 | Metabolism/PK | clozapine | null | Patients with the rs72547516 TT genotype and may have decreased metabolism of clozapine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence clozapine metabolism. This annotation only covers the pharmacokinetic relationship between rs72547516 and clozapine and does not inc... | https://www.clinpgx.org/clinicalAnnotation/1156497684 |
1156738774 | rs2231142 | rs2231142 | ABCG2 | GG | 3 | Metabolism/PK | simvastatin | null | Patients with the rs2231142 GG genotype may have reduced exposure to simvastatin as compared to patients with the TT genotype. This annotation only covers the pharmacokinetic relationship between rs2231142 and simvastatin and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a ... | https://www.clinpgx.org/clinicalAnnotation/1156738774 |
1156738774 | rs2231142 | rs2231142 | ABCG2 | GT | 3 | Metabolism/PK | simvastatin | null | Patients with the rs2231142 GT genotype may have reduced exposure to simvastatin as compared to patients with the TT genotype. This annotation only covers the pharmacokinetic relationship between rs2231142 and simvastatin and does not include evidence about clinical outcomes. This drug-variant pair has been assigned a ... | https://www.clinpgx.org/clinicalAnnotation/1156738774 |
1156738774 | rs2231142 | rs2231142 | ABCG2 | TT | 3 | Metabolism/PK | simvastatin | null | Patients with the rs2231142 TT genotype may have increased exposure to simvastatin as compared to patients with the GT or GG genotypes. This annotation only covers the pharmacokinetic relationship between rs2231142 and simvastatin and does not include evidence about clinical outcomes. This drug-variant pair has been as... | https://www.clinpgx.org/clinicalAnnotation/1156738774 |
1157204541 | rs1150226 | rs1150226 | HTR3A | AA | 3 | Efficacy | clozapine | Schizophrenia | Patients with the AA genotype as part of a haplotype rs2276302-rs1062613-rs1150226 and Schizophrenia who are treated with clozapine may have a decreased response as compared to patients with the GG genotype as part of a haplotype rs2276302-rs1062613-rs1150226. However, only a trend of association is reported. Other gen... | https://www.clinpgx.org/clinicalAnnotation/1157204541 |
1157204541 | rs1150226 | rs1150226 | HTR3A | GA | 3 | Efficacy | clozapine | Schizophrenia | Patients with the GA genotype as part of a haplotype rs2276302-rs1062613-rs1150226 and Schizophrenia who are treated with clozapine may have an increased response as compared to patients with the AA genotype as part of a haplotype rs2276302-rs1062613-rs1150226. However, only a trend of association is reported. Other ge... | https://www.clinpgx.org/clinicalAnnotation/1157204541 |
1157204541 | rs1150226 | rs1150226 | HTR3A | GG | 3 | Efficacy | clozapine | Schizophrenia | Patients with the GG genotype as part of a haplotype rs2276302-rs1062613-rs1150226 and Schizophrenia who are treated with clozapine may have an increased response as compared to patients with the AA genotype as part of a haplotype rs2276302-rs1062613-rs1150226. However, only a trend of association is reported. Other ge... | https://www.clinpgx.org/clinicalAnnotation/1157204541 |
1157877076 | rs776746 | rs776746 | CYP3A5 | CC | 3 | Dosage;Toxicity | sunitinib | Renal Cell Carcinoma | Patients with the CC genotype and Carcinoma who are treated with sunitinib may have a decreased, but not absent, risk for dose reductions due to toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to sunitinib. | https://www.clinpgx.org/clinicalAnnotation/1157877076 |
1157877076 | rs776746 | rs776746 | CYP3A5 | CT | 3 | Dosage;Toxicity | sunitinib | Renal Cell Carcinoma | Patients with the CT genotype and Carcinoma who are treated with sunitinib may have a decreased, but not absent, risk for dose reductions due to toxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to sunitinib. | https://www.clinpgx.org/clinicalAnnotation/1157877076 |
1157877076 | rs776746 | rs776746 | CYP3A5 | TT | 3 | Dosage;Toxicity | sunitinib | Renal Cell Carcinoma | Patients with the TT genotype and Carcinoma who are treated with sunitinib may have an increased risk for dose reductions due to toxicity as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to sunitinib. | https://www.clinpgx.org/clinicalAnnotation/1157877076 |
1158793019 | rs4149081 | rs4149081 | SLCO1B1 | AA | 3 | Efficacy | rosuvastatin | Coronary Disease | Patients with the AA genotype and Coronary Disease may have an increased response to rosuvastatin as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to rosuvastatin. | https://www.clinpgx.org/clinicalAnnotation/1158793019 |
1158793019 | rs4149081 | rs4149081 | SLCO1B1 | AG | 3 | Efficacy | rosuvastatin | Coronary Disease | Patients with the AG genotype and Coronary Disease may have an increased response to rosuvastatin as compared to patients with the GG genotype and a decreased response to rosuvastatin as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to rosuvastatin... | https://www.clinpgx.org/clinicalAnnotation/1158793019 |
1158793019 | rs4149081 | rs4149081 | SLCO1B1 | GG | 3 | Efficacy | rosuvastatin | Coronary Disease | Patients with the GG genotype and Coronary Disease may have a decreased response to rosuvastatin as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to rosuvastatin. | https://www.clinpgx.org/clinicalAnnotation/1158793019 |
1183490952 | rs2244613 | rs2244613 | CES1 | GG | 3 | Toxicity | dabigatran | Atrial Fibrillation | Patients with the GG genotype and Atrial Fibrillation who are treated with dabigatran may have 1) a decreased adjusted trough concentrations of dabigatran, 2) a decreased, but not absent, risk for bleeding when treated with dabigatran as compared to patients with the TT genotype. Other genetic and clinical factors may ... | https://www.clinpgx.org/clinicalAnnotation/1183490952 |
1183490952 | rs2244613 | rs2244613 | CES1 | GT | 3 | Toxicity | dabigatran | Atrial Fibrillation | Patients with the GT genotype and Atrial Fibrillation who are treated with dabigatran may have 1) a decreased adjusted trough concentrations of dabigatran, 2) a decreased, but not absent, risk for bleeding when treated with dabigatran as compared to patients with the TT genotype. Other genetic and clinical factors may ... | https://www.clinpgx.org/clinicalAnnotation/1183490952 |
1183490952 | rs2244613 | rs2244613 | CES1 | TT | 3 | Toxicity | dabigatran | Atrial Fibrillation | Patients with the TT genotype and Atrial Fibrillation may have an increased risk for bleeding when treated with dabigatran as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence a patient's risk for bleeding. | https://www.clinpgx.org/clinicalAnnotation/1183490952 |
1183490957 | rs9922316 | rs9922316 | PRKCB | GG | 3 | Other | dexmedetomidine | null | Patients with the GG genotype may have decreased dexmedetomidine ED50 values for drug-induced dorsal hand vein constriction as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to dexmedetomidine. | https://www.clinpgx.org/clinicalAnnotation/1183490957 |
1183490957 | rs9922316 | rs9922316 | PRKCB | TG | 3 | Other | dexmedetomidine | null | Patients with the TG genotype may have increased dexmedetomidine ED50 values for drug-induced dorsal hand vein constriction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to dexmedetomidine. | https://www.clinpgx.org/clinicalAnnotation/1183490957 |
1183490957 | rs9922316 | rs9922316 | PRKCB | TT | 3 | Other | dexmedetomidine | null | Patients with the TT genotype may have increased dexmedetomidine ED50 values for drug-induced dorsal hand vein constriction as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to dexmedetomidine. | https://www.clinpgx.org/clinicalAnnotation/1183490957 |
1183490962 | rs1800544 | rs1800544 | ADRA2A | CC | 3 | Other | dexmedetomidine | null | Patients with the CC genotype may have an increased sedative response to dexmedetomidine as compared to patients with the GG or GC genotype. Other genetic and clinical factors may also influence a patient's response to dexmedetomidine. | https://www.clinpgx.org/clinicalAnnotation/1183490962 |
1183490962 | rs1800544 | rs1800544 | ADRA2A | GC | 3 | Other | dexmedetomidine | null | Patients with the GC genotype may have a decreased sedative response to dexmedetomidine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to dexmedetomidine. | https://www.clinpgx.org/clinicalAnnotation/1183490962 |
1183490962 | rs1800544 | rs1800544 | ADRA2A | GG | 3 | Other | dexmedetomidine | null | Patients with the GG genotype may have a decreased sedative response to dexmedetomidine as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to dexmedetomidine. | https://www.clinpgx.org/clinicalAnnotation/1183490962 |
1183490967 | rs2283265 | rs2283265 | DRD2 | AA | 3 | Efficacy | disulfiram | Cocaine dependence | Patients with the AA genotype may have an increased likelihood of response when treated with disulfiram as compared to patients with the CC. Other genetic and clinical factors may also influence a patient's response to disulfiram. | https://www.clinpgx.org/clinicalAnnotation/1183490967 |
1183490967 | rs2283265 | rs2283265 | DRD2 | AC | 3 | Efficacy | disulfiram | Cocaine dependence | Patients with the AC genotype may have an increased likelihood of response when treated with disulfiram as compared to patients with the CC. Other genetic and clinical factors may also influence a patient's response to disulfiram. | https://www.clinpgx.org/clinicalAnnotation/1183490967 |
1183490967 | rs2283265 | rs2283265 | DRD2 | CC | 3 | Efficacy | disulfiram | Cocaine dependence | Patients with the CC genotype may have a decreased likelihood of response when treated with disulfiram as compared to patients with the AC or AA. Other genetic and clinical factors may also influence a patient's response to disulfiram. | https://www.clinpgx.org/clinicalAnnotation/1183490967 |
1183490978 | rs1800497 | rs1800497 | ANKK1 | AA | 3 | Efficacy | disulfiram | Cocaine dependence | Patients with the AA genotype may have an increased likelihood of response when treated with disulfiram as compared to patients with the GG. Other genetic and clinical factors may also influence a patient's response to disulfiram. | https://www.clinpgx.org/clinicalAnnotation/1183490978 |
1183490978 | rs1800497 | rs1800497 | ANKK1 | AG | 3 | Efficacy | disulfiram | Cocaine dependence | Patients with the AG genotype may have an increased likelihood of response when treated with disulfiram as compared to patients with the GG. Other genetic and clinical factors may also influence a patient's response to disulfiram. | https://www.clinpgx.org/clinicalAnnotation/1183490978 |
1183490978 | rs1800497 | rs1800497 | ANKK1 | GG | 3 | Efficacy | disulfiram | Cocaine dependence | Patients with the GG genotype may have a decreased likelihood of response when treated with disulfiram as compared to patients with the AG or AA. Other genetic and clinical factors may also influence a patient's response to disulfiram. | https://www.clinpgx.org/clinicalAnnotation/1183490978 |
1183490994 | rs702553 | rs702553 | PDE4D | AA | 3 | Efficacy | diuretics | Nephrosclerosis | Patients with the AA genotype and Nephrosclerosis may have a higher baseline mean arterial blood pressure when treated with diuretics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to diuretics. | https://www.clinpgx.org/clinicalAnnotation/1183490994 |
1183490994 | rs702553 | rs702553 | PDE4D | AT | 3 | Efficacy | diuretics | Nephrosclerosis | Patients with the AT genotype and Nephrosclerosis may have a higher baseline mean arterial blood pressure when treated with diuretics as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to diuretics. | https://www.clinpgx.org/clinicalAnnotation/1183490994 |
1183490994 | rs702553 | rs702553 | PDE4D | TT | 3 | Efficacy | diuretics | Nephrosclerosis | Patients with the TT genotype and Nephrosclerosis may have a lower baseline mean arterial blood pressure when treated with diuretics as compared to patients with the AA or AT genotype. Other genetic and clinical factors may also influence a patient's response to diuretics. | https://www.clinpgx.org/clinicalAnnotation/1183490994 |
1183490999 | rs10494366 | rs10494366 | NOS1AP | GG | 3 | Toxicity | dolasetron;granisetron | null | Patients with the GG genotype undergoing surgery who are exposed to dolasetron or granisetron as part of anesthetic management may have a decreased, but not absent, risk for QTc interval prolongation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for... | https://www.clinpgx.org/clinicalAnnotation/1183490999 |
1183490999 | rs10494366 | rs10494366 | NOS1AP | TG | 3 | Toxicity | dolasetron;granisetron | null | Patients with the TG genotype undergoing surgery who are exposed to dolasetron or granisetron as part of anesthetic management may have an increased risk for QTc interval prolongation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for QTc interval pr... | https://www.clinpgx.org/clinicalAnnotation/1183490999 |
1183490999 | rs10494366 | rs10494366 | NOS1AP | TT | 3 | Toxicity | dolasetron;granisetron | null | Patients with the TT genotype undergoing surgery who are exposed to dolasetron or granisetron as part of anesthetic management may have an increased risk for QTc interval prolongation as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for QTc interval pr... | https://www.clinpgx.org/clinicalAnnotation/1183490999 |
1183491004 | rs1800566 | rs1800566 | NQO1 | AA | 3 | Efficacy | Platinum compounds | Neoplasms | Patients with the rs1800566 AA genotype who are treated with platinum chemotherapy regimens may have decreased overall survival as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence survival. | https://www.clinpgx.org/clinicalAnnotation/1183491004 |
1183491004 | rs1800566 | rs1800566 | NQO1 | AG | 3 | Efficacy | Platinum compounds | Neoplasms | Patients with the rs1800566 AG genotype who are treated with platinum chemotherapy regimens may have decreased overall survival as compared to patients with the GG genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence survival. | https://www.clinpgx.org/clinicalAnnotation/1183491004 |
1183491004 | rs1800566 | rs1800566 | NQO1 | GG | 3 | Efficacy | Platinum compounds | Neoplasms | Patients with the rs1800566 GG genotype who are treated with platinum chemotherapy regimens may have increased overall survival as compared to patients with the AA genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence survival. | https://www.clinpgx.org/clinicalAnnotation/1183491004 |
1183491021 | rs8187710 | rs8187710 | ABCC2 | AA | 3 | Other | calcein;lopinavir | null | Patients with the AA genotype may have higher accumulation of lopinavir or calcein and reduced ABCC2-mediated efflux of lopinavir as compared to the patients with the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of lopinavir or calcein. | https://www.clinpgx.org/clinicalAnnotation/1183491021 |
1183491021 | rs8187710 | rs8187710 | ABCC2 | AG | 3 | Other | calcein;lopinavir | null | The AG genotype was not studied. | https://www.clinpgx.org/clinicalAnnotation/1183491021 |
1183491021 | rs8187710 | rs8187710 | ABCC2 | GG | 3 | Other | calcein;lopinavir | null | Patients with the GG genotype may have lower accumulation of lopinavir or calcein and increased ABCC2-mediated efflux of lopinavir as compared to the patients with the AA genotype. Other genetic and clinical factors may also influence a patient's metabolism of lopinavir or calcein. | https://www.clinpgx.org/clinicalAnnotation/1183491021 |
1183491026 | rs8187710 | rs8187710 | ABCC2 | AA | 3 | Efficacy | lopinavir | HIV infectious disease | Patients with the AA genotype who are treated with lopinavir may have a higher accumulation of lopinavir in peripheral blood mononuclear cells as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to lopinavir. | https://www.clinpgx.org/clinicalAnnotation/1183491026 |
1183491026 | rs8187710 | rs8187710 | ABCC2 | AG | 3 | Efficacy | lopinavir | HIV infectious disease | Patients with the AG genotype who are treated with lopinavir may have a higher accumulation of lopinavir in peripheral blood mononuclear cells as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to lopinavir. | https://www.clinpgx.org/clinicalAnnotation/1183491026 |
1183491026 | rs8187710 | rs8187710 | ABCC2 | GG | 3 | Efficacy | lopinavir | HIV infectious disease | Patients with the GG genotype who are treated with lopinavir may have a lower accumulation of lopinavir in peripheral blood mononuclear cells as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's response to lopinavir. | https://www.clinpgx.org/clinicalAnnotation/1183491026 |
1183491035 | rs1801394 | rs1801394 | MTRR | AA | 3 | Efficacy | folic acid;vitamin b-complex, plain | Migraine with Aura | Female patients with the AA genotype and Migraine who are treated with folic acid and a vitamin b-complex may have decreased severity of pain as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's severity of pain. | https://www.clinpgx.org/clinicalAnnotation/1183491035 |
1183491035 | rs1801394 | rs1801394 | MTRR | AG | 3 | Efficacy | folic acid;vitamin b-complex, plain | Migraine with Aura | Female patients with the AG genotype and Migraine who are treated with folic acid and a vitamin b-complex may have decreased severity of pain as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's severity of pain. | https://www.clinpgx.org/clinicalAnnotation/1183491035 |
1183491035 | rs1801394 | rs1801394 | MTRR | GG | 3 | Efficacy | folic acid;vitamin b-complex, plain | Migraine with Aura | Female patients with the GG genotype and Migraine who are treated with folic acid and a vitamin b-complex may have increased severity of pain as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence a patient's severity of pain. | https://www.clinpgx.org/clinicalAnnotation/1183491035 |
1183491044 | rs3745274 | rs3745274 | CYP2B6 | GG | 3 | Other | mitotane | Adrenocortical Carcinoma | Patients with the GG genotype and Adrenocortical Carcinoma who are treated with mitotane may have lower mitotane plasma concentrations as compared to patients with the TT or TG genotype. Other genetic and clinical factors may also influence a patient's metabolism of mitotane. | https://www.clinpgx.org/clinicalAnnotation/1183491044 |
1183491044 | rs3745274 | rs3745274 | CYP2B6 | TG | 3 | Other | mitotane | Adrenocortical Carcinoma | Patients with the TG genotype and Adrenocortical Carcinoma who are treated with mitotane may have higher mitotane plasma concentrations as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of mitotane. | https://www.clinpgx.org/clinicalAnnotation/1183491044 |
1183491044 | rs3745274 | rs3745274 | CYP2B6 | TT | 3 | Other | mitotane | Adrenocortical Carcinoma | Patients with the TT genotype and Adrenocortical Carcinoma who are treated with mitotane may have higher mitotane plasma concentrations as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's metabolism of mitotane. | https://www.clinpgx.org/clinicalAnnotation/1183491044 |
1183491055 | rs6787801 | rs6787801 | P2RY12 | AA | 3 | Efficacy | cangrelor | null | Patients with the AA genotype may have higher ADP-induced peak platelet aggregation when exposed to cangrelor as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to cangrelor. | https://www.clinpgx.org/clinicalAnnotation/1183491055 |
1183491055 | rs6787801 | rs6787801 | P2RY12 | AG | 3 | Efficacy | cangrelor | null | Patients with the AG genotype may have lower ADP-induced peak platelet aggregation when exposed to cangrelor as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to cangrelor. | https://www.clinpgx.org/clinicalAnnotation/1183491055 |
1183491055 | rs6787801 | rs6787801 | P2RY12 | GG | 3 | Efficacy | cangrelor | null | Patients with the GG genotype may have lower ADP-induced peak platelet aggregation when exposed to cangrelor as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to cangrelor. | https://www.clinpgx.org/clinicalAnnotation/1183491055 |
1183491098 | rs11887534 | rs11887534 | ABCG8 | CC | 3 | Efficacy | atorvastatin | Coronary Artery Disease;Hypercholesterolemia | Patients with the CC genotype who are treated with atorvastatin may have a better response to treatment (measured by higher decreases in LDL-cholesterol) as compared to patients with the GG genotype. This may be influenced by rs3808607 genotype, with an increased response in patients with the rs3808607 TT genotype. Oth... | https://www.clinpgx.org/clinicalAnnotation/1183491098 |
1183491098 | rs11887534 | rs11887534 | ABCG8 | CG | 3 | Efficacy | atorvastatin | Coronary Artery Disease;Hypercholesterolemia | Patients with the CG genotype who are treated with atorvastatin may have a better response to treatment (measured by higher decreases in LDL-cholesterol) as compared to patients with the GG genotype. However, this association was not observed in the majority of studies. This may be influenced by rs3808607 genotype. Oth... | https://www.clinpgx.org/clinicalAnnotation/1183491098 |
1183491098 | rs11887534 | rs11887534 | ABCG8 | GG | 3 | Efficacy | atorvastatin | Coronary Artery Disease;Hypercholesterolemia | Patients with the GG genotype who are treated with atorvastatin may have a decreased response to treatment (measured by lower decreases in LDL-cholesterol) as compared to patients with the CC genotype. This association may be influenced by rs3808607 genotype. Several studies show no association as compared to the CG ge... | https://www.clinpgx.org/clinicalAnnotation/1183491098 |
1183491140 | rs776746 | rs776746 | CYP3A5 | CC | 3 | Efficacy | atorvastatin | null | Patients with the CC genotype who are treated with atorvastatin may have a better response to treatment as compared to patients with the TT genotype. Conflicting evidence was seen by population type. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment. | https://www.clinpgx.org/clinicalAnnotation/1183491140 |
1183491140 | rs776746 | rs776746 | CYP3A5 | CT | 3 | Efficacy | atorvastatin | null | Patients with the CT genotype who are treated with atorvastatin may have a better response to treatment as compared to patients with the TT genotype. Conflicting evidence was seen by population type. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment. | https://www.clinpgx.org/clinicalAnnotation/1183491140 |
1183491140 | rs776746 | rs776746 | CYP3A5 | TT | 3 | Efficacy | atorvastatin | null | Patients with the TT genotype who are treated with atorvastatin may have a reduced response to treatment as compared to patients with the CC or CT genotype. Conflicting evidence was seen by population type. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment. | https://www.clinpgx.org/clinicalAnnotation/1183491140 |
1183491157 | rs776746 | rs776746 | CYP3A5 | CC | 3 | Efficacy | lovastatin | Arteriosclerosis | Patients with the CC genotype and Arteriosclerosis who are treated with lovastatin may have a better response to treatment (measured by higher reductions in total cholesterol) as compared to patients with the CT genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment. | https://www.clinpgx.org/clinicalAnnotation/1183491157 |
1183491157 | rs776746 | rs776746 | CYP3A5 | CT | 3 | Efficacy | lovastatin | Arteriosclerosis | Patients with the CT genotype and Arteriosclerosis who are treated with lovastatin may have a reduced response to treatment (measured by lower reductions in total cholesterol) as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to statin treatment. | https://www.clinpgx.org/clinicalAnnotation/1183491157 |
1183491157 | rs776746 | rs776746 | CYP3A5 | TT | 3 | Efficacy | lovastatin | Arteriosclerosis | Patients with the TT genotype and Arteriosclerosis were not examined in the study, however; patients with the CT genotype who are treated with lovastatin may have a reduced response to treatment (measured by lower reductions in total cholesterol) as compared to patients with the CC genotype. Other genetic and clinical ... | https://www.clinpgx.org/clinicalAnnotation/1183491157 |
1183491162 | rs776746 | rs776746 | CYP3A5 | CC | 4 | Other | simvastatin | Hypercholesterolemia;Myalgia | Patients with the CC genotype may have higher plasma concentrations and reduced clearance of simvastatin as compared to patients with the TT genotype. This does not seem to affect response to treatment or risk of myalgia or myopathy. Other genetic and clinical factors may also influence a patient's metabolism of simvas... | https://www.clinpgx.org/clinicalAnnotation/1183491162 |
1183491162 | rs776746 | rs776746 | CYP3A5 | CT | 4 | Other | simvastatin | Hypercholesterolemia;Myalgia | Patients with the CT genotype may have higher plasma concentrations and reduced clearance of simvastatin as compared to patients with the TT genotype, or may have lower plasma concentrations and higher clearance of simvastatin as compared to patients with the CC genotype. This does not seem to affect response to treatm... | https://www.clinpgx.org/clinicalAnnotation/1183491162 |
1183491162 | rs776746 | rs776746 | CYP3A5 | TT | 4 | Other | simvastatin | Hypercholesterolemia;Myalgia | Patients with the TT genotype may have lower plasma concentrations and higher clearance of simvastatin as compared to patients with the CC genotype. This does not seem to affect response to treatment or risk of myalgia or myopathy. Other genetic and clinical factors may also influence a patient's metabolism of simvasta... | https://www.clinpgx.org/clinicalAnnotation/1183491162 |
1183491175 | rs776746 | rs776746 | CYP3A5 | CC | 3 | Efficacy | rosuvastatin | Myocardial Infarction | Patients with the CC genotype and Myocardial Infarction who are treated with rosuvastatin may be more likely to achieve target LDL levels as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to rosuvastatin treatment. | https://www.clinpgx.org/clinicalAnnotation/1183491175 |
1183491175 | rs776746 | rs776746 | CYP3A5 | CT | 3 | Efficacy | rosuvastatin | Myocardial Infarction | Patients with the CT genotype and Myocardial Infarction who are treated with rosuvastatin may be more likely to achieve target LDL levels as compared to patients with the TT genotype, or may be less likely to achieve target LDL levels as compared to patients with the CC genotype. Other genetic and clinical factors may ... | https://www.clinpgx.org/clinicalAnnotation/1183491175 |
1183491175 | rs776746 | rs776746 | CYP3A5 | TT | 3 | Efficacy | rosuvastatin | Myocardial Infarction | Patients with the TT genotype and Myocardial Infarction who are treated with rosuvastatin may be less likely to achieve target LDL levels as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to rosuvastatin treatment. | https://www.clinpgx.org/clinicalAnnotation/1183491175 |
1183491189 | rs17161788 | rs17161788 | CYP3A5 | CC | 3 | Efficacy | atorvastatin | Hypercholesterolemia | Patients with the CC genotype and Hypercholesterolemia may have a better response to atorvastatin treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment. | https://www.clinpgx.org/clinicalAnnotation/1183491189 |
1183491189 | rs17161788 | rs17161788 | CYP3A5 | CT | 3 | Efficacy | atorvastatin | Hypercholesterolemia | Patients with the CT genotype and Hypercholesterolemia may have a better response to atorvastatin treatment as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment. | https://www.clinpgx.org/clinicalAnnotation/1183491189 |
1183491189 | rs17161788 | rs17161788 | CYP3A5 | TT | 3 | Efficacy | atorvastatin | Hypercholesterolemia | Patients with the TT genotype and Hypercholesterolemia may have a reduced response to atorvastatin treatment as compared to patients with the CT or CC genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment. | https://www.clinpgx.org/clinicalAnnotation/1183491189 |
1183491214 | rs1057868 | rs1057868 | POR | CC | 3 | Other | midazolam | null | Patients with the CC genotype may have an decreased metabolic ratio of midazolam as compared to patients with the TT genotype. However, contradictory findings are reported with an increased metabolic ratio of midazolam as compared to patients with the CT genotype in CYP3A5*1 patients. Other genetic and clinical factors... | https://www.clinpgx.org/clinicalAnnotation/1183491214 |
1183491214 | rs1057868 | rs1057868 | POR | CT | 3 | Other | midazolam | null | Patients with the TC genotype may have a decreased metabolic ratio of midazolam as compared to patients with the TT genotype. However, contradictory findings are reported with a decreased metabolic ratio of midazolam as compared to patients with the CC genotype in CYP3A5*1 patients. Other genetic and clinical factors m... | https://www.clinpgx.org/clinicalAnnotation/1183491214 |
1183491214 | rs1057868 | rs1057868 | POR | TT | 3 | Other | midazolam | null | Patients with the TT genotype may have an increased metabolic ratio of midazolam as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's metabolism of midazolam. | https://www.clinpgx.org/clinicalAnnotation/1183491214 |
1183491262 | rs1042173 | rs1042173 | SLC6A4 | AA | 3 | Efficacy | ondansetron | Alcohol abuse | Patients with the AA genotype who are treated with ondansetron may have increased treatment response among patients carrying the SLC6A4 promoter length polymorphism long/long genotype as compared to patients with the AC or CC genotype. Other genetic and clinical factors may also influence a patient's response to ondans... | https://www.clinpgx.org/clinicalAnnotation/1183491262 |
1183491262 | rs1042173 | rs1042173 | SLC6A4 | AC | 3 | Efficacy | ondansetron | Alcohol abuse | Patients with the AC genotype who are treated with ondansetron may have decreased treatment response among patients carrying the SLC6A4 promoter length polymorphism long/long genotype as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to ondansetron. | https://www.clinpgx.org/clinicalAnnotation/1183491262 |
1183491262 | rs1042173 | rs1042173 | SLC6A4 | CC | 3 | Efficacy | ondansetron | Alcohol abuse | Patients with the CC genotype who are treated with ondansetron may have decreased treatment response among patients carrying the SLC6A4 promoter length polymorphism long/long genotype as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to ondansetron. | https://www.clinpgx.org/clinicalAnnotation/1183491262 |
1183491278 | CYP3A5*1, CYP3A5*3 | null | CYP3A5 | *1/*1 | 3 | Efficacy;Toxicity | atorvastatin | Myalgia | Patients with the *1/*1 genotype who are treated with atorvastatin may have an increased response to treatment as compared to patients with the *3/*3 genotype. Other genetic and clinical factors may also influence a patient's response to atorvastatin treatment. | https://www.clinpgx.org/clinicalAnnotation/1183491278 |
1183491278 | CYP3A5*1, CYP3A5*3 | null | CYP3A5 | *1/*3 | 3 | Efficacy;Toxicity | atorvastatin | Myalgia | Patients with the *1/*3 genotype who are treated with atorvastatin 1) may have an increased response to treatment 2) may have a decreased risk of myalgia and a lower degree of muscle damage as compared to patients with the *3/*3 genotype. Other genetic and clinical factors may also influence a patient's response to ato... | https://www.clinpgx.org/clinicalAnnotation/1183491278 |
1183491278 | CYP3A5*1, CYP3A5*3 | null | CYP3A5 | *3/*3 | 3 | Efficacy;Toxicity | atorvastatin | Myalgia | Patients with the *3/*3 genotype who are treated with atorvastatin 1) may have a decreased response to treatment as compared to patients with the *1/*3 and *1/*1 genotype 2) may have an increased risk of myalgia and a greater degree of muscle damage as compared to patients with the *1/*3 genotype. Other genetic and cli... | https://www.clinpgx.org/clinicalAnnotation/1183491278 |
1183491298 | rs1801368 | rs1801368 | MAD1L1 | CC | 3 | Efficacy | carboplatin;paclitaxel | Ovarian Neoplasms | Patients with the CC genotype and Ovarian Neoplasms who are treated with carboplatin and paclitaxel may have higher biochemical response, optimal cytoreduction, and sensitivity to the treatment as compared to patients with the TT or TC genotype. Other genetic and clinical factors may also influence a patient's response... | https://www.clinpgx.org/clinicalAnnotation/1183491298 |
1183491298 | rs1801368 | rs1801368 | MAD1L1 | TC | 3 | Efficacy | carboplatin;paclitaxel | Ovarian Neoplasms | Patients with the TC genotype and Ovarian Neoplasms who are treated with carboplatin and paclitaxel may have lower decreased biochemical response, cytoreduction, and sensitivity to the induction chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's ... | https://www.clinpgx.org/clinicalAnnotation/1183491298 |
1183491298 | rs1801368 | rs1801368 | MAD1L1 | TT | 3 | Efficacy | carboplatin;paclitaxel | Ovarian Neoplasms | Patients with the TT genotype and Ovarian Neoplasms who are treated with carboplatin and paclitaxel may have lower decreased biochemical response, cytoreduction, and sensitivity to the induction chemotherapy as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's ... | https://www.clinpgx.org/clinicalAnnotation/1183491298 |
1183491310 | CYP3A4*1, CYP3A4*4 | null | CYP3A4 | *1/*1 | 3 | Efficacy | simvastatin | Hyperlipidemias | Patients with the *1/*1 diplotype and Hyperlipidemia may have a reduced response to simvastatin treatment as compared to patients with the *1/*4 genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment. | https://www.clinpgx.org/clinicalAnnotation/1183491310 |
1183491310 | CYP3A4*1, CYP3A4*4 | null | CYP3A4 | *1/*4 | 3 | Efficacy | simvastatin | Hyperlipidemias | Patients with the *1/*4 diplotype and Hyperlipidemia may have a better response to simvastatin treatment as compared to patients with the *1/*1 genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment. | https://www.clinpgx.org/clinicalAnnotation/1183491310 |
1183491333 | rs4673 | rs4673 | CYBA | AA | 3 | Other | simvastatin | Hypercholesterolemia | Patients with the AA genotype and Hypercholesterolemia may benefit more from simvastatin treatment due to an increased reduction in DNA damage as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment. | https://www.clinpgx.org/clinicalAnnotation/1183491333 |
1183491333 | rs4673 | rs4673 | CYBA | AG | 3 | Other | simvastatin | Hypercholesterolemia | Patients with the AG genotype and Hypercholesterolemia may benefit more from simvastatin treatment due to an increased reduction in DNA damage as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment. | https://www.clinpgx.org/clinicalAnnotation/1183491333 |
1183491333 | rs4673 | rs4673 | CYBA | GG | 3 | Other | simvastatin | Hypercholesterolemia | Patients with the GG genotype and Hypercholesterolemia may benefit less from simvastatin treatment due to a lower reduction in DNA damage as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to simvastatin treatment. | https://www.clinpgx.org/clinicalAnnotation/1183491333 |
1183491354 | rs2298826 | rs2298826 | SLC6A5 | AA | 3 | Toxicity | haloperidol | Schizophrenia | Patients with the AA genotype and Schizophrenia who are treated with haloperidol may have an increased risk for rapid rise of motor side effects at the beginning of the treatment as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's risk for treatment side... | https://www.clinpgx.org/clinicalAnnotation/1183491354 |
1183491354 | rs2298826 | rs2298826 | SLC6A5 | AG | 3 | Toxicity | haloperidol | Schizophrenia | Patients with the AG genotype and Schizophrenia who are treated with haloperidol may have a decreased risk for rapid rise of motor side effects at the beginning of the treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for treatment side effect... | https://www.clinpgx.org/clinicalAnnotation/1183491354 |
1183491354 | rs2298826 | rs2298826 | SLC6A5 | GG | 3 | Toxicity | haloperidol | Schizophrenia | Patients with the GG genotype and Schizophrenia who are treated with haloperidol may have a decreased risk for rapid rise of motor side effects at the beginning of the treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for treatment side effect... | https://www.clinpgx.org/clinicalAnnotation/1183491354 |
1183491359 | rs4783961 | rs4783961 | CETP | AA | 3 | Efficacy | fluvastatin | Hypercholesterolemia | Patients with the AA genotype and Hypercholesterolemia may have a reduced response to fluvastatin treatment (determined by a lower change in HDL-C levels) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment. | https://www.clinpgx.org/clinicalAnnotation/1183491359 |
1183491359 | rs4783961 | rs4783961 | CETP | AG | 3 | Efficacy | fluvastatin | Hypercholesterolemia | Patients with the AG genotype and Hypercholesterolemia may have a reduced response to fluvastatin treatment (determined by a lower change in HDL-C levels) as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment. | https://www.clinpgx.org/clinicalAnnotation/1183491359 |
1183491359 | rs4783961 | rs4783961 | CETP | GG | 3 | Efficacy | fluvastatin | Hypercholesterolemia | Patients with the GG genotype and Hypercholesterolemia may have a better response to fluvastatin treatment (determined by higher change in HDL-C levels) as compared to patients with the AG or AA genotype. Other genetic and clinical factors may also influence a patient's response to fluvastatin treatment. | https://www.clinpgx.org/clinicalAnnotation/1183491359 |
1183491364 | rs1801133 | rs1801133 | MTHFR | AA | 3 | Efficacy | folic acid;vitamin b-complex, plain | null | Female patients with the AA genotype and Migraine who are treated with folic acid and a vitamin b-complex may have an increased severity of pain lesser reduction in homocysteine as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's severity of pain. This d... | https://www.clinpgx.org/clinicalAnnotation/1183491364 |
1183491364 | rs1801133 | rs1801133 | MTHFR | AG | 3 | Efficacy | folic acid;vitamin b-complex, plain | null | Female patients with the AG genotype and Migraine who are treated with folic acid and a vitamin b-complex may have a decreased severity of pain greater reduction in homocysteine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's severity of pain. This drug-va... | https://www.clinpgx.org/clinicalAnnotation/1183491364 |
1183491364 | rs1801133 | rs1801133 | MTHFR | GG | 3 | Efficacy | folic acid;vitamin b-complex, plain | null | Female patients with the GG genotype and Migraine who are treated with folic acid and a vitamin b-complex may have a decreased severity of pain and greater reduction in homocysteine as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's severity of pain. This dru... | https://www.clinpgx.org/clinicalAnnotation/1183491364 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.